Skip to main content
OpenTrials

Clinical trial condition

Relapsed Diffuse Large B-Cell Lymphoma

Explore clinical trials studying Relapsed Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.

10 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Relapsed Diffuse Large B-Cell Lymphoma trial results

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Compassionate Cancer Care Medical Group Fountain Valley, California, United States
  • Boca Raton Regional Hospital Boca Raton, Florida, United States
  • BRCR Medical Center Inc. Hollywood, Florida, United States
  • BRCR Medical Center Inc. Plantation, Florida, United States
View all 50 locations
View Trial Details
Completed

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

NCT04833114

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie Graz, Austria
  • LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie Leoben, Austria
  • Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie Linz, Austria
  • Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie Linz, Austria
View all 64 locations
View Trial Details
Completed

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

NCT05068440

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital Hefei, Anhui, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
View all 25 locations
View Trial Details
Completed

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

NCT05267054

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 19 locations
View Trial Details
Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216

Conditions
Hemic and Lymphatic Diseases, High Grade B-cell Lymphoma (HGBCL), Immune System Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California San Diego (UCSD) La Jolla, California, United States
  • Stanford University Palo Alto, California, United States
View all 36 locations
View Trial Details
Completed

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Cedar Sinai Medical Center Los Angeles, California, United States
  • UCLA Medical Center Los Angeles, California, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of California San Diego Moores Cancer Center La Jolla, California, United States
  • Redlands Community Hospital Redlands, California, United States
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • Baptist MD Anderson Cancer Center Jacksonville, Florida, United States
View all 144 locations
View Trial Details
Active, Not Recruiting

Copanlisib Plus Venetoclax in R/R DLBCL

NCT04572763

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Siteman Cancer Center at Washington University St Louis, Missouri, United States
View Trial Details

Related conditions